Flexible and wearable electronic technology is in great demand with the rising of smart electronic systems. Among this, exploring multifunctional with high performance at low cost has attracted extensive attention...

Polylactic acid (PLA) and poly(3-hydroxybutyrate-co-4-hydroxybutyrate) (P(3HB-co-4HB)) nanofibers were prepared by melt extrusion of immiscible blends of PLA/polyvinyl alcohol (PVA) and P(3HB-co-4HB)/PVA via in situ formation of microfibrils during the melt extrusion process. The morphology of the blends and nanofibers after removal of PVA with water was studied using scanning electron microscopy. The intermolecular interactions in the blends were studied by Fourier-transform infrared spectroscopy. The compatibility of the components of the PVA/PLA blends was better than that of the PVA/P(3HB-co-4HB) blends. By varying the process conditions, the average diameter of the PLA nanofibers could be controlled in the range of 78–150 nm and that of the P(3HB-co-4HB) nanofibers could be controlled in the range of 274–424 nm.

Objectives: Wuzhi Capsule (WZC) is often administrated with tacrolimus in liver transplant patients to reduce the toxicity of tacrolimus and relieve the financial burden of patients. We aimed to investigate the interaction between Wuzhi Capsule (WZC) and tacrolimus in liver transplant patients.Methods: We applied the LC-MS/MS analytical method previously established to study the pharmacokinetic characteristics of the analytes in 15 liver transplant patients. CYP3A5 genotypes were determined in 15 donors and recipients, and they were categorized into CYP3A5 expressers and non-expressers respectively.Results: The influences of CYP3A5 in donors and recipients on the pharmacokinetics of tacrolimus with or without WZC were also studied. We found that 1) WZC could influence the metabolism of tacrolimus, which shortened the Tmax of tacrolimus and decreased V/F and CL/F. 2) Moreover, our results showed that, in donors, the CL/F of tacrolimus were significantly lower in CYP3A5 (CYP3A5*1) expressers (decreased from 24.421 to 12.864) and non-expressers (decreased from 23.532 to 11.822) when co-administration with WZC. For recipients, the decreased trend of CL/F of tacrolimus was seen when co-administrated with WZC by 15.376 and 12.243 in CYP3A5 expressers and non-expressers, respectively.Conclusion: In this study, the pharmacokinetics effects of WZC on tacrolimus were identified. The co-administration of WZC can increase the tacrolimus blood concentration in Chinese liver transplant patients in clinical practice.